250 related articles for article (PubMed ID: 30552464)
1. In vitro-to-in vivo extrapolation (IVIVE) by PBTK modeling for animal-free risk assessment approaches of potential endocrine-disrupting compounds.
Fabian E; Gomes C; Birk B; Williford T; Hernandez TR; Haase C; Zbranek R; van Ravenzwaay B; Landsiedel R
Arch Toxicol; 2019 Feb; 93(2):401-416. PubMed ID: 30552464
[TBL] [Abstract][Full Text] [Related]
2. Cross-species conservation of endocrine pathways: a critical analysis of tier 1 fish and rat screening assays with 12 model chemicals.
Ankley GT; Gray LE
Environ Toxicol Chem; 2013 Apr; 32(5):1084-7. PubMed ID: 23401061
[TBL] [Abstract][Full Text] [Related]
3. A testing strategy for the identification of mammalian, systemic endocrine disruptors with particular focus on steroids.
Kolle SN; Ramirez T; Kamp HG; Buesen R; Flick B; Strauss V; van Ravenzwaay B
Regul Toxicol Pharmacol; 2012 Jul; 63(2):259-78. PubMed ID: 22554500
[TBL] [Abstract][Full Text] [Related]
4. Fish Physiologically Based Toxicokinetic Modeling Approach for In Vitro-In Vivo and Cross-Species Extrapolation of Endocrine-Disrupting Chemicals in Risk Assessment.
Xie R; Xu Y; Ma M; Wang Z
Environ Sci Technol; 2024 Feb; 58(8):3677-3689. PubMed ID: 38354091
[TBL] [Abstract][Full Text] [Related]
5. Effect of estrogenic binary mixtures in the yeast estrogen screen (YES).
Ramirez T; Buechse A; Dammann M; Melching-Kollmuß S; Woitkowiak C; van Ravenzwaay B
Regul Toxicol Pharmacol; 2014 Oct; 70(1):286-96. PubMed ID: 25017362
[TBL] [Abstract][Full Text] [Related]
6. In vitro to in vivo extrapolation for predicting human equivalent dose of phenolic endocrine disrupting chemicals: PBTK model development, biological pathways, outcomes and performance.
Xie R; Wang X; Xu Y; Zhang L; Ma M; Wang Z
Sci Total Environ; 2023 Nov; 897():165271. PubMed ID: 37422235
[TBL] [Abstract][Full Text] [Related]
7. The role of fit-for-purpose assays within tiered testing approaches: A case study evaluating prioritized estrogen-active compounds in an in vitro human uterotrophic assay.
Beames T; Moreau M; Roberts LA; Mansouri K; Haider S; Smeltz M; Nicolas CI; Doheny D; Phillips MB; Yoon M; Becker RA; McMullen PD; Andersen ME; Clewell RA; Hartman JK
Toxicol Appl Pharmacol; 2020 Jan; 387():114774. PubMed ID: 31783037
[TBL] [Abstract][Full Text] [Related]
8. A case study on quantitative in vitro to in vivo extrapolation for environmental esters: Methyl-, propyl- and butylparaben.
Campbell JL; Yoon M; Clewell HJ
Toxicology; 2015 Jun; 332():67-76. PubMed ID: 25839974
[TBL] [Abstract][Full Text] [Related]
9. Development and evaluation of a harmonized whole body physiologically based pharmacokinetic (PBPK) model for flutamide in rats and its extrapolation to humans.
Sharma RP; Kumar V; Schuhmacher M; Kolodkin A; Westerhoff HV
Environ Res; 2020 Mar; 182():108948. PubMed ID: 31841869
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of OASIS QSAR Models Using ToxCast™ in Vitro Estrogen and Androgen Receptor Binding Data and Application in an Integrated Endocrine Screening Approach.
Bhhatarai B; Wilson DM; Price PS; Marty S; Parks AK; Carney E
Environ Health Perspect; 2016 Sep; 124(9):1453-61. PubMed ID: 27152837
[TBL] [Abstract][Full Text] [Related]
11. Key learnings from performance of the U.S. EPA Endocrine Disruptor Screening Program (EDSP) Tier 1 in vitro assays.
LeBaron MJ; Coady KK; O'Connor JC; Nabb DL; Markell LK; Snajdr S; Sue Marty M
Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):23-42. PubMed ID: 24515815
[TBL] [Abstract][Full Text] [Related]
12. Assessment of the analgesic dipyrone as a possible (anti)androgenic endocrine disruptor.
Passoni MT; Kristensen MN; Morais RN; Woitkowiak C; Boareto AC; da Silva Amaral BA; Grechi N; Dalsenter PR; Munkboel CH; Styrishave B; Kristensen DM; Gomes C; van Ravenzwaay B; Martino-Andrade AJ
Toxicol Lett; 2018 Mar; 285():139-147. PubMed ID: 29289696
[TBL] [Abstract][Full Text] [Related]
13. Selected bisphenols and phthalates screened for estrogen and androgen disruption by in silico and in vitro methods.
Dvorakova M; Kejlová K; Rucki M; Jírová D
Neuro Endocrinol Lett; 2018 Dec; 39(5):409-416. PubMed ID: 30664347
[TBL] [Abstract][Full Text] [Related]
14. Endocrine-disrupting potential of bisphenol A, bisphenol A dimethacrylate, 4-n-nonylphenol, and 4-n-octylphenol in vitro: new data and a brief review.
Bonefeld-Jørgensen EC; Long M; Hofmeister MV; Vinggaard AM
Environ Health Perspect; 2007 Dec; 115 Suppl 1(Suppl 1):69-76. PubMed ID: 18174953
[TBL] [Abstract][Full Text] [Related]
15. Predicting the in vivo developmental toxicity of fenarimol from in vitro toxicity data using PBTK modelling-facilitated reverse dosimetry approach.
Bhateria M; Taneja I; Karsauliya K; Sonker AK; Shibata Y; Sato H; Singh SP; Hisaka A
Toxicol Appl Pharmacol; 2024 Mar; 484():116879. PubMed ID: 38431230
[TBL] [Abstract][Full Text] [Related]
16. Incorporation of metabolic enzymes to improve predictivity of reporter gene assay results for estrogenic and anti-androgenic activity.
van Vugt-Lussenburg BMA; van der Lee RB; Man HY; Middelhof I; Brouwer A; Besselink H; van der Burg B
Reprod Toxicol; 2018 Jan; 75():40-48. PubMed ID: 29162470
[TBL] [Abstract][Full Text] [Related]
17. Alternative methods in vitro for screening of endocrine disruptors.
Dvořáková M; Kejlová K; Bendová H; Rucki M; Kohout P; Vavrouš A; Jírová D
Neuro Endocrinol Lett; 2016 Dec; 37(Suppl1):123-131. PubMed ID: 28263540
[TBL] [Abstract][Full Text] [Related]
18. Alternatives to in vivo tests to detect endocrine disrupting chemicals (EDCs) in fish and amphibians--screening for estrogen, androgen and thyroid hormone disruption.
Scholz S; Renner P; Belanger SE; Busquet F; Davi R; Demeneix BA; Denny JS; Léonard M; McMaster ME; Villeneuve DL; Embry MR
Crit Rev Toxicol; 2013 Jan; 43(1):45-72. PubMed ID: 23190036
[TBL] [Abstract][Full Text] [Related]
19. Re-evaluation of the first synthetic estrogen, 1-keto-1,2,3, 4-tetrahydrophenanthrene, and bisphenol A, using both the ovariectomised rat model used in 1933 and additional assays.
Ashby J; Odum J; Paton D; Lefevre PA; Beresford N; Sumpter JP
Toxicol Lett; 2000 Jun; 115(3):231-8. PubMed ID: 10814893
[TBL] [Abstract][Full Text] [Related]
20. A Comparison of ToxCast Test Results with In Vivo and Other In Vitro Endpoints for Neuro, Endocrine, and Developmental Toxicities: A Case Study Using Endosulfan and Methidathion.
Silva M; Pham N; Lewis C; Iyer S; Kwok E; Solomon G; Zeise L
Birth Defects Res B Dev Reprod Toxicol; 2015 Apr; 104(2):71-89. PubMed ID: 26017137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
